STOCK TITAN

Theriva Biologics announces 1-for-30 reverse stock split

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Theriva Biologics, Inc. (TOVX) announced a board-approved 1-for-30 reverse stock split of its issued, outstanding and authorized common stock. It is expected to take effect at 11:59 p.m. Eastern Time on December 1, 2026, with split-adjusted trading expected to begin at the December 2, 2026 market open. The company says the split is intended to meet NYSE American per-share price requirements. Nevada law permits the board to implement it without shareholder approval when outstanding and authorized shares are reduced proportionally.

Outstanding common shares are expected to fall from 45,892,668 to approximately 1,529,756, excluding fractional shares; authorized common shares are expected to decline from 350,000,000 to 11,666,666. Warrants, options and shares reserved under equity incentive plans will be adjusted proportionally. TOVX will continue trading on NYSE American under the same ticker.

Filing Explained

Theriva says holders whose pre-split share counts are not evenly divisible by 30 will not receive fractional shares; instead, each will automatically receive an additional fractional share to bring the post-split holding up to the next whole share.

Item 8.01 Other Events Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Reverse stock split ratio 1-for-30 Announced split of common stock
Outstanding common shares before split 45,892,668 shares Before the reverse stock split
Expected outstanding common shares after split Approximately 1,529,756 shares Excluding fractional shares
Authorized common shares before split 350,000,000 shares Before the reverse stock split
Authorized common shares after split 11,666,666 shares Following the proportional reduction
reverse stock split technical
"announced today a reverse stock split"
A reverse stock split reduces a company's number of outstanding shares while raising the price per share proportionally, so the total value of each investor's holding is unchanged; a 1-for-10 split turns 100 shares worth $1 each into 10 shares worth $10 each. Companies often do this to regain compliance with an exchange's minimum price rule or to attract investors who avoid very low-priced stocks.
split-adjusted basis technical
"begin trading on a split-adjusted basis"
An adjustment to historical share prices and share counts that reflects past stock splits or reverse splits so that old data lines up with the current number of shares. Think of it like resizing an old photograph so it matches a new frame: it keeps price charts, returns and per‑share metrics comparable over time, which matters to investors who need accurate performance, valuation and trend analysis.
fractional share financial
"No fractional shares will be issued"
A fractional share is a portion of a single stock that is worth less than one full share, like owning a slice of a pizza instead of the whole pie. It lets investors buy and hold part of expensive stocks or spread small amounts of money across many companies, which helps with diversification and regular investing; dividends and price changes affect fractional shares proportionally, though some rights and trading rules can vary by provider.
oncolytic adenovirus medical
"new oncolytic adenovirus platform"
An oncolytic adenovirus is a virus based on adenovirus that has been modified to preferentially infect and kill cancer cells and often to activate the immune system against tumors—imagine a guided missile that both destroys cancer cells and raises an alarm for the body's defenses. Investors should note these therapies can deliver large upside if clinical trials prove effective, but they carry substantial clinical, manufacturing and regulatory risks that can cause big valuation swings.
Split Ratio 1-for-30 reverse split
Effective Date December 1, 2026
Shares Before Split 45,892,668
Shares After Split 1,529,756

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is the TOVX reverse stock split ratio and when does it take effect?

One new share for every 30 existing shares, with the split expected to take effect at 11:59 p.m. Eastern Time on December 1, 2026. TOVX is expected to begin split-adjusted trading at the market open on December 2, 2026.

How many TOVX common shares are expected after the reverse split?

The outstanding common share count is expected to fall from 45,892,668 to approximately 1,529,756 shares, excluding the effect of fractional shares.

Do TOVX holders need to exchange shares after the reverse split?

Holders whose shares are in brokerage accounts or held in “street name” are not required to take action to effect the exchange. The transfer agent will send instructions to holders of record with stock certificates regarding exchanging old certificates for new ones, should they wish to do so.

How will fractional TOVX shares be handled?

No fractional shares will be issued; holders who would otherwise be entitled to one will automatically receive an additional fractional share to round up to the next whole share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false 0000894158 0000894158 2026-11-20 2026-11-20 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

  

Date of Report (Date of earliest event reported): November 20, 2026

 

THERIVA BIOLOGICS, INC.

(Exact name of registrant as specified in its charter)

 

Nevada   001-12584   13-3808303
(State or other jurisdiction of
incorporation)
  (Commission File No.)   (IRS Employer Identification
No.)

 

9605 Medical Center Drive, Suite 270

Rockville, Maryland 20850

(Address of principal executive offices and zip code)

 

(301) 417-4364

Registrant’s telephone number, including area code

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
¨ Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12)
   
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which
registered
Common stock, par value $0.001 per share TOVX NYSE American

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

 

Item 8.01. Other Events.

 

On November 20, 2026, Theriva Biologics, Inc., a Nevada corporation (the “Company”), issued a press release announcing that the Company’s Board of Directors approved a 1-for-30 reverse stock split of the Company’s issued, outstanding and authorized common stock, pursuant to Section 78.207 of the Nevada Revised Statutes (the “Reverse Stock Split”). The Reverse Stock Split is anticipated to be effective as of 11:59 p.m. (Eastern Time) on December 1, 2026, and it is expected that the Company’s common stock will begin trading on a split-adjusted basis as of the open of trading on December 2, 2026. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

 

Item 9.01. Financial Statements and Exhibits.

  

(d) Exhibits.

 

The following exhibits are filed with this Current Report on Form 8-K:

 

Exhibit
Number
  Description
99.1   Press Release issued by Theriva Biologics, Inc., dated November 20, 2026
104   Cover Page Interactive Data File (embedded within the XBRL document)

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: November 20, 2026 THERIVA BIOLOGICS, INC.
       
  By: /s/ Steven A. Shallcross
    Name: Steven A. Shallcross
    Title: Chief Executive Officer and Chief Financial Officer

 

 

 

 

Exhibit 99.1

 

Theriva™ Biologics Announces Reverse Stock Split

 

Rockville, MD, November 20, 2026 – Theriva™ Biologics, Inc. (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, announced today a reverse stock split of its authorized and issued and outstanding common stock, par value $0.001 per share, at a ratio of one (1) share of common stock for every thirty (30) shares of common stock, effective as of 11:59 p.m. (Eastern Time) on December 1, 2026 (the “Effective Date”). The Company’s common stock will begin trading on a split-adjusted basis when the market opens on December 2, 2026. The reverse stock split was authorized by the Company’s Board of Directors on November 13, 2026. Pursuant to the laws of the State of Nevada, the Company’s state of incorporation, the Company’s Board of Directors has the authority to effect a reverse stock split without shareholder approval if the number of authorized shares of common stock and the number of outstanding shares of common stock are proportionally reduced. The Company will file a certificate of change to its articles of incorporation, as amended, with the Secretary of State of Nevada to effect the reverse stock split. The Company’s common stock will continue to trade on the NYSE American under the stock ticker “TOVX” but will trade under the new CUSIP number 87164U607.

 

As a result of the reverse split, each thirty (30) pre-split shares of common stock outstanding will automatically combine into one (1) new share of common stock without any action on the part of the holders, and the number of outstanding common shares will be reduced from 45,892,668 shares to approximately 1,529,756 shares without taking into account fractional shares. The number of authorized shares of common stock will be proportionally reduced from 350,000,000 shares to 11,666,666 shares.

 

The reverse stock split is being effected to ensure that the Company can meet the per share price requirements of the NYSE American, the Company's current listing exchange.

 

No fractional shares will be issued as a result of the reverse stock split. Stockholders who otherwise would be entitled to a fractional share because they hold a number of shares not evenly divisible by the one (1) for thirty (30) reverse split ratio will automatically be entitled to receive an additional fractional share of the Company’s common stock to round up to the next whole share.

 

Proportionate adjustments will also be made to the number of shares of common stock issuable upon exercise of, and the exercise price of, the Company’s outstanding warrants and stock options, and to the number of shares of common stock reserved for issuance under the Company’s equity incentive plans.

 

The Company’s transfer agent, Equiniti Trust Company, which is also acting as the exchange agent for the reverse split, will send instructions to stockholders of record who hold stock certificates regarding the exchange of their old certificates for new certificates, should they wish to do so. Stockholders who hold their shares in brokerage accounts or “street name” are not required to take action to effect the exchange of their shares.

 

About Theriva™ Biologics, Inc.

 

Theriva™ Biologics (NYSE American: TOVX) is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. The Company’s subsidiary Theriva Biologics, S.L., has been developing a new oncolytic adenovirus platform designed for intravenous (IV), intravitreal and intratumoral delivery to trigger tumor cell death, improve access of co-administered cancer therapies to the tumor, and promote a robust and sustained anti-tumor response by the patient’s immune system. The Company’s lead clinical-stage candidate is VCN-01 (zabilugene almadenorepvec), an oncolytic adenovirus designed to replicate selectively within tumor cells, and to degrade the tumor stroma barrier that serves as a significant physical and immunosuppressive barrier to cancer treatment. For more information, please visit Theriva™ Biologics’ website at www.therivabio.com.

 

 

 

 

Forward-Looking Statement

 

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions, and include statements regarding our planned reverse stock split, including its expected effective date and the expected commencement of trading on a split-adjusted basis. These forward-looking statements are based on management's expectations and assumptions as of the date of this press release and are subject to a number of risks and uncertainties, many of which are difficult to predict that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the reverse stock split having the desired effect; the Company’s ability to maintain compliance with the continued listing standards of the NYSE American; the Company’s ability to raise capital and/or enter into one or more strategic alternatives, that may include a business combination, merger or reverse merger; the Company’s ability to obtain development funding and/or partnerships; the Company’s ability to receive any milestone or royalty payments from Biossil; the Company’s commencement of planned clinical trials, which remains subject to sufficient financing; the Company’s ability to finalize protocols for future clinical trials evaluating VCN-01; results of future trials supporting further clinical development of VCN-01 and supporting the benefits of more frequent repeated dosing of VCN-01; the Company’s ability to reach clinical milestones when anticipated, including the ability to continue to enroll patients as planned; generating clinical data that establishes VCN-01 may improve patient outcomes in cancer patients; the ability to obtain regulatory approval for commercialization of product candidates or to comply with ongoing regulatory requirements, including approval of VCN-01 to treat cancer patients; regulatory limitations relating to the Company’s ability to promote or commercialize its product candidates for the specific indications; acceptance of the Company’s product candidates in the marketplace; the successful development, marketing or sale of the Company’s products; developments by competitors that render such products obsolete or non-competitive; the Company’s ability to maintain license agreements; the continued maintenance and growth of the Company’s patent estate; the ability to continue to remain well financed; and other factors described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 and its other filings with the SEC, including subsequent periodic reports on Forms 10-Q and current reports on Form 8-K. The information in this release is provided only as of the date of this release, and Theriva Biologics undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.

 

For further information, please contact:

 

Investor Relations:

Kevin Gardner

LifeSci Advisors, LLC

kgardner@lifesciadvisors.com

###

 

 

 

Filing Exhibits & Attachments

4 documents

Keep reading